Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price reached a new 52-week low on Monday . The stock traded as low as GBX 4.50 and last traded at GBX 4.70, with a volume of 366805 shares changing hands. The stock had previously closed at GBX 5.
Allergy Therapeutics Stock Up 9.9%
The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48. The company has a fifty day moving average price of GBX 5.67 and a 200 day moving average price of GBX 8.22. The company has a market cap of £330.56 million, a PE ratio of -5.38, a price-to-earnings-growth ratio of -30.70 and a beta of 0.83.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Featured Articles
- Five stocks we like better than Allergy Therapeutics
- 2 “Cheap for a Reason” Airline Stocks That May Be Worth the Risk
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
